Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy.

[1]  G. Lippi,et al.  Statins for Primary Prevention of Cardiovascular Disease. , 2017, Trends in pharmacological sciences.

[2]  E. Falk,et al.  The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30 824 Europeans: the Copenhagen General Population Study , 2015, European heart journal.

[3]  N. Cook,et al.  A proposal to incorporate trial data into a hybrid ACC/AHA algorithm for the allocation of statin therapy in primary prevention. , 2015, Journal of the American College of Cardiology.

[4]  John W McEvoy,et al.  An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. , 2015, Annals of internal medicine.

[5]  Nancy R Cook,et al.  Comparing Cardiovascular Risk Prediction Scores , 2015, Annals of Internal Medicine.

[6]  N. Cook,et al.  Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. , 2014, JAMA internal medicine.

[7]  B. Gersh,et al.  Do current clinical trials meet society's needs?: a critical review of recent evidence. , 2014, Journal of the American College of Cardiology.

[8]  R. Frikke-Schmidt,et al.  Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease , 2014 .

[9]  S. Grundy,et al.  2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. , 2014, Journal of the American College of Cardiology.

[10]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[11]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[12]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[13]  O. Franco,et al.  Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. , 2014, JAMA.

[14]  Jbs Board.  Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) , 2014, Heart.

[15]  R. Blumenthal,et al.  Concepts and Controversies: The 2013 American College of Cardiology/American Heart Association Risk Assessment and Cholesterol Treatment Guidelines , 2014, Annals of Internal Medicine.

[16]  N. Wong.  Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014 .

[17]  Nancy R Cook,et al.  Statins: new American guidelines for prevention of cardiovascular disease , 2013, The Lancet.

[18]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[19]  Paul M Ridker,et al.  A trial-based approach to statin guidelines. , 2013, JAMA.

[20]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[21]  Shah Ebrahim,et al.  [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]. , 2013, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[22]  S. Grundy,et al.  The case for treating hypercholesterolemia at an earlier age: moving toward consensus. , 2012, Journal of the American College of Cardiology.

[23]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[24]  N. Timpson,et al.  The Effect of Elevated Body Mass Index on Ischemic Heart Disease Risk: Causal Estimates from a Mendelian Randomisation Approach , 2012, PLoS medicine.

[25]  N. Cook,et al.  Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes , 2011, Menopause.

[26]  D. Lloyd‐Jones.  Cardiovascular risk prediction: basic concepts, current status, and future directions. , 2010, Circulation.

[27]  I. Graham,et al.  Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. , 2009, Journal of the American College of Cardiology.

[28]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[29]  Yasuo Ohashi,et al.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[30]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[31]  徳重 明央,et al.  137) 僧帽弁弁輪部に付着した血管腫の一例(第95回日本循環器学会九州地方会) , 2004 .

[32]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[33]  R. Collins,et al.  Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial , 2001, Journal of hypertension.

[34]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[35]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[36]  Børge G. Nordestgaard,et al.  Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. , 2014, JAMA internal medicine.

[37]  R. Collins,et al.  Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial , 2012, Drugs.

[38]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.